Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24467203 | 1.00 | KCNH2 (0.34) | KCNH2CYP2D6HRH3KAT2BDRD2 | |
| SCHEMBL20161616 | 0.81 | ATM (0.33) | — | |
| SCHEMBL27089692 | 0.79 | HRH3 (0.39) | KCNH2CYP2D6HRH3 | |
| SCHEMBL27089688 | 0.77 | KAT2B (0.33) | KCNH2KAT2BDRD2DRD3CCR2 | |
| SCHEMBL20161755 | 0.77 | KAT2B (0.33) | KCNH2KAT2BDRD2DRD3CCR2 | |
| SCHEMBL24467188 | 0.77 | KAT2B (0.33) | KCNH2KAT2BDRD2DRD3CCR2 | |
| SCHEMBL24467177 | 0.76 | KAT2B (0.32) | KAT2BDRD2DRD3 | |
| SCHEMBL23366017 | 0.76 | KAT2B (0.32) | KAT2BDRD2DRD3 | |
| SCHEMBL27089698 | 0.76 | KAT2B (0.32) | KAT2BDRD2DRD3 | |
| SCHEMBL24467172 | 0.73 | KAT2B (0.31) | KCNH2KAT2BDRD2DRD3CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | IL2, NFATC1, IL2RA | KCNH2 3854/4885CYP2D6 4530/4885HRH3 1227/4885 |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | IL2, NFATC1, IL2RA | KCNH2 3854/4885CYP2D6 4530/4885HRH3 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.